You are here » Media » Press releases

Press Releases

Entries for 2013

September 11, 2013

Jeannette R. Jakus, MD, MBA, has been selected as the 2013 recipient of the American Academy of Dermatology Translational Biotechnology Fellowship, a partnership of the American Academy of Dermatology and Galderma Research & Development, SNC.


Posted in: Press release

August 26, 2013

the First and Only FDA-Approved Topical treatment Specifically Developed and Indicated for the Facial Erythema of Rosacea 
Mirvaso Works Quickly and Lasts for up to 12 Hours2

FT. WORTH, Texas – August 26, 2013 – Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) has approved Mirvaso® (brimonidine) topical gel, 0.33%* for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older.1 Applied once-daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours.2  Galderma expects Mirvaso to be available in pharmacies September 2013.


Posted in: Press release

June 06, 2013

Galderma today announced that it has initiated clinical development of a novel muscle relaxant, based on an advanced formulation of botulinum toxin, with the first cohort of patients already treated in the initial clinical study.

“Muscle relaxants are a key medical solution aesthetic physicians can use to create balanced and optimal results for their patients. We aim to strengthen our portfolio with a new and proprietary muscle relaxant in territories where Galderma does not have access to Azzalure/Dysport, such as North America” commented Humberto C. Antunes, President and CEO of Galderma. “We look forward to rapidly advancing this innovative product in countries where we do not currently promote Azzalure or Dysport in aesthetics.”


Posted in: Press release

April 25, 2013

SCHAUMBURG, ILL. and SOPHIA ANTIPOLIS, FRANCE (April 25, 2013) –The American Academy of Dermatology (Academy), in partnership with Galderma Research & Development, SNC is pleased to announce the creation of the American Academy of Dermatology Translational Biotechnology Fellowship. The new fellowship will offer a dermatologist the opportunity to work in drug development and translational medical research at Galderma’s R&D facility located in Sophia Antipolis, France. This learning opportunity will allow the physician to advance science and explore career options within a pharmaceutical industry setting.

Galderma will host two one-year fellowships, one beginning in fall 2013 and one beginning in fall 2014 at Sophia Antipolis, the largest corporate-funded facility in the world dedicated to skin research.


Posted in: Press release

April 23, 2013

Mississauga, Ontario, Canada – April 23, 2013 – Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of...


Posted in: Press release

 1 / 1  

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world



We are committed

See all videos